title: Effects of growth hormone treatment on the leptin system and on energy expenditure in abdominally obese men.
abstract: The present study has examined the short- and long-term effects of growth hormone (GH) treatment on the leptin system and energy expenditure. Thirty male individuals with abdominal obesity were randomised to GH or placebo treatment in a 9-month, double-blind study. The dose of GH was 9.5 microg/kg, administered subcutaneously every evening. Serum leptin concentrations were measured by a human leptin RIA. Total RNA was isolated from adipose tissue biopsies and leptin mRNA levels were determined by a semi-quantitative reverse transcriptase-PCR assay. Body composition was determined by potassium-40 and the basal metabolic rate (BMR) was measured by a computerised, ventilated, open-hood system. As compared with placebo, an overall decrease in serum leptin concentrations as assessed by the area under the curve (AUC) (P < 0.05) and an increase in BMR (AUC, P < 0.05) were observed during GH treatment. The overall GH-induced changes were due to marked changes in serum leptin concentrations and BMR after 6 weeks of treatment. After 9 months of GH treatment there was a significant reduction in body fat (BF) while serum leptin concentrations and BMR did not differ from baseline values. Leptin mRNA levels did not change over the study period. We speculate that long-term GH treatment induces a new energy balance steady state with decreased BF stores. The effects of GH on the leptin system is suggested to be of importance for the maintenance of a lower BF mass.
authors.affiliation: Research Centre for Endocrinology and Metabolism, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
authors.forename: C
authors.initials: C
authors.lastname: Karlsson
authors.forename: K
authors.initials: K
authors.lastname: Stenlöf
authors.forename: G
authors.initials: G
authors.lastname: Johannsson
authors.forename: P
authors.initials: P
authors.lastname: Mårin
authors.forename: P
authors.initials: P
authors.lastname: Björntorp
authors.forename: B A
authors.initials: BA
authors.lastname: Bengtsson
authors.forename: B
authors.initials: B
authors.lastname: Carlsson
authors.forename: L M
authors.initials: LM
authors.lastname: Carlsson
authors.forename: L
authors.initials: L
authors.lastname: Sjöström
mesh_terms: D000005:Abdomen; D000368:Aged; D004311:Double-Blind Method; D004734:Energy Metabolism / Q000187:drug effects*; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D020738:Leptin; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D011506:Proteins / Q000378:metabolism*; D012044:Regression Analysis; D013963:Thyroid Hormones / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020738:Leptin; D011506:Proteins; D013963:Thyroid Hormones; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone